The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Disease characteristics of ultra-long-term multiple myeloma survivors
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the characteristics of ultra-long-term multiple myeloma survivors who achieved disease-free survival. He highlights that a small fraction of patients (approximately 4%) lived without evidence of active disease for 15 years or more, with their characteristics compatible with lower stages on the International Staging System (ISS) and standard cytogenetics. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
In our center, the Department of Clinical Therapeutics, we evaluated patients with multiple myeloma who started treatment and had at least a 15-year follow-up. So we observed that about 4% of these patients had at least a 15-year disease-free survival, the overwhelming majority of these patients were in complete response and those that were tested also were MRD negative. At baseline, the characteristics of these patients were compatible with low-stage ISS and standard cytogenetics...
In our center, the Department of Clinical Therapeutics, we evaluated patients with multiple myeloma who started treatment and had at least a 15-year follow-up. So we observed that about 4% of these patients had at least a 15-year disease-free survival, the overwhelming majority of these patients were in complete response and those that were tested also were MRD negative. At baseline, the characteristics of these patients were compatible with low-stage ISS and standard cytogenetics. So we conclude that even with older regimens we can have a small fraction of patients with myeloma that may live without evidence of active disease for 15 years or more and I believe that this is at least one prerequisite to start talking about operational cure and we believe that in the future this number will increase since we will be using more active regimens at the frontline setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
SWIXX: Honoraria; BEIGENE: Honoraria; JANSSEN: Honoraria; BMS: Honoraria; GSK: Honoraria; TAKEDA: Honoraria; MENARINI: Honoraria; REGENERON: Honoraria; SANOFI: Honoraria; AMGEN: Honoraria, Membership on an entity’s Board of Directors or advisory committees; ASTRA ZENECA: Honoraria.
